Proposal of an improved histological sub-typing system for lung adenocarcinoma - significant prognostic values for stage I disease

International Journal of Clinical and Experimental Pathology

Volumn 3, Issue 4, 2010, Pages 348-366

  Okudela, Koji ^a   Woo, Tetsukan ^a   Mitsui, Hideaki ^a   Yazawa, Takuya ^a   Shimoyamada, Hiroaki ^a   Tajiri, Michihiko ^b   Ogawa, Nobuo ^b   Masuda, Munetaka ^a   Kitamura, Hitoshi ^a  

^a YOKOHAMA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b Kanagawa Prefectural Cardiovascular and Respiratory Center Hospital   (Japan)

Author keywords

Altered sub typing system; Lung adenocarcinoma; Morphometric profiling; Prognostic value; Stage I

Indexed keywords

ADENOCARCINOMA; ARTICLE; CANCER STAGING; CLASSIFICATION; DISEASE FREE SURVIVAL; HUMAN; IMMUNOHISTOCHEMISTRY; KAPLAN MEIER METHOD; LUNG TUMOR; MORTALITY; PATHOLOGY; PROGNOSIS;

ADENOCARCINOMA; DISEASE-FREE SURVIVAL; HUMANS; IMMUNOHISTOCHEMISTRY; KAPLAN-MEIERS ESTIMATE; LUNG NEOPLASMS; NEOPLASM STAGING; PROGNOSIS;

EID: 77955876130     PISSN: None     EISSN: 19362625     Source Type: Journal    
DOI: None     Document Type: Article

References (15)

1. Spira A, Ettinger DS. Multidisciplinary management of lung cancer. N Engl J Med 2004;350:379-392.
2. Travis WD, Brambilla E, Muller-Hermelink HK, Harris CC (Eds). World Health Organization Classification of Tumors. Pathology and Genetics of the Lung, Pleura, Thymus and Heart, IARC Press, Lyon, 2004.
3. Asamura H, Goya T, Koshiishi Y, Sohara Y, Egu chi K, Mori M, et al. A Japanese lung cancer registry study: prognosis of 13,010 resected lung cancers. J Thorac Oncol 2008;3:46-52.
4. Noguchi M, Morikawa A, Kawasaki M, Matsuno Y, Yamada T, Hirohashi S et al. Small adenocarcinoma of the lung. Histologic characteristics and prognosis. Cancer. 1995;75:2844-2852.
5. Ou SH, Zell JA, Ziogas A, Anton-Culver H. Prognostic factors for survival of stage I non-small cell lung cancer patients: a population-based analysis of 19,702 stage I patients in the California cancer registry from 1989 to 2003. Cancer. 2007;110:1532-1541.
6. Tsuchiya T, Akamine S, Muraoka M, Kamohara R, Tsuji K, Urabe S, et al. Stage IA non-small cell lung cancer: Vessel invasion is a poor prognostic factor and a new target of adjuvant chemotherapy. Lung Cancer 2007;56:341-348.
7. Yokose T, Suzuki K, Nagai K, Nishiwaki Y, Sasaki S, Ochiai A. Favorable and unfavorable morphological prognostic factors in peripheral adenocarcinoma of the lung 3 cm or less in diameter. Lung Cancer. 2000;29:179-188.
8. Hamada C, Tanaka F, Ohta M, Fujimura S, Kodama K, Imaizumi M, Wada H. Meta-analysis of postoperative adjuvant chemotherapy with tegaful-uracil in non-small-cell lung cancer. J Clin Oncol 2005;23:4999-5006.
9. Kato H, Ichinose Y, Ohta M, Hata E, Tsubota N, Tada H, et al. A randomized trial of adjuvant chemotherapy with uracil-tegafur for adenocarcinoma of the lung. N Engl J Med 2004;350:1713-1721.
10. Okudela K, Woo T, Mitsui H, Yazawa T, Shimoyamda H, Tajiri M, et al. Morphometric Profiling of Lung Cancers - its association with clinicopathologic, biological and molecular genetic features- Am J Surg Pahtol. 2010 in press [doi: 10.1097/PAS.0b013e3181c79a6f]
11. Mountain CF. Revisions in the international system for staging lung cancer. Chest. 1997;111:1710-1717.
12. Bertheau P, Cazals-Hatem D, Meignin V, Roquancourt A, Verola O, Lesourd A, et al. Variability of immunohistochemical reactivity on stored paraffin slides. J Clin Pathol 1998;51:370-374.
13. DiVito KA, Charette LA, Rimm DL, Camp RL. Long-term preservation of antigenicity on tissue microarrays. Lab Invest 2004;84:1071-1078.
14. Suzuki K, Yokose T, Yoshida J, Nishimura M, Takahashi K, Nagai K, et al. Prognostic significance of the size of central fibrosis in peripheral adenocarcinoma of the lung. Ann Thorac Surg. 2000;69:893-897.
15. Woo T, Okudela K, Yazawa T, Wada N, Ogawa N, Ishiwa N, et al. Prognostic value of KRAS mutations and Ki-67 expression in stage I lung adenocarcinomas. Lung Cancer. 2009;65:355-62.